Y. Robert Li

Cardiovascular Diseases

• Gebundenes Buch

Produktbeschreibung

This book systematically integrates essentials, advances, and clinical correlations for cardiovascular drugs. The author covers both fundamentals and pharmacology of cardiovascular drugs, as well as their applications to treat cardiovascular diseases. In addition, the text presents evidence-based pharmacotherapeutics in the management of common cardiovascular diseases and conditions. Written in an accessible style and consistent format, and using case presentations and study questions, the book serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues.

---

Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases.

- Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases
- Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology
- Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases
- Uses case presentations and study questions to enhance understanding of the material
- Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues

Produktdetails

• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 14591537000
• 1. Auflage
• Seitenzahl: 502
• Erscheinungstermin: 27. März 2015
• Englisch
• Abmessung: 286mm x 221mm x 31mm
• Gewicht: 666g
• ISBN-13: 9780470915370
• ISBN-10: 0470915374
• Artikelnr.: 41753118

Autorenporträt

Y. Robert Li is Professor and Founding Chair of the Department of Pharmacology and Assistant Dean for Biomedical Research at Campbell University and holds Adjunct Professor appointments at Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Virginia-Maryland Regional College of Veterinary Medicine, and University of North Carolina at Greensboro. He is an author of over 110 peer-reviewed publications, three monographs, and numerous book chapters and serves on the editorial boards of several leading journals. Dr. Li has over 20 years of teaching experience in the areas of biomedical sciences, free radical biology, toxicology, pharmacology, and therapeutics.

Inhaltsangabe

PREFACE xix LIST OF ABBREVIATIONS xxii UNIT I GENERAL INTRODUCTION 1 1
Introduction to Cardiovascular Diseases 3 1.1 Overview 3 1.2 Definition of
Cardiovascular Diseases 3 1.3 Classification of Cardiovascular Diseases 3
1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases 5 1.5 Risk
Factors of Cardiovascular Diseases 9 1.6 Prevention and Control of
Cardiovascular Diseases 10 1.7 Cardiovascular Risk Prediction and
Evidence?]Based Treatments 15 1.8 Summary of Chapter Key Points 18 1.9
Self-Assessment Questions 18 References 19 2 Introduction to Principles of
Pharmacology 21 2.1 Overview 21 2.2 Definitions and History 21 2.3
Pharmacological Paradigm: the Central Dogma in Pharmacology 24 2.4
Principles of Drug Discovery, Development, and Regulation 31 2.5
Pharmacology Subspecialties 32 2.6 Introduction to Cardiovascular
Pharmacology 32 2.7 Summary of Chapter Key Points 38 2.8 Self?]Assessment
Questions 39 References 40 UNIT II DYSLIPIDEMIAS 43 3 Overview of
Dyslipidemias and Drug Therapy 45 3.1 Introduction 45 3.2 Lipoprotein
Metabolism 45 3.3 Dyslipidemias and Genetic Lipoprotein Disorders 51 3.4
Mechanistically Based Drug Therapy of Dyslipidemias 51 3.5 Summary of
Chapter Key Points 53 3.6 Self?]Assessment Questions 54 References 54 4
Drugs for Dyslipidemias 56 4.1 Overview 56 4.2 Statins 56 4.3 Bile Acid
Sequestrants 64 4.4 Cholesterol Absorption Inhibitors 69 4.5 Fibrates 72
4.6 Niacin 75 4.7 New Drugs for HoFH 80 4.8 Phytosterols and Phytostanols
83 4.9 Omega?]3 Fatty Acids 86 4.10 Emerging Therapeutic Modalities for
Dyslipidemias 88 4.11 Summary of Chapter Key Points 93 4.12 Self-Assessment
Questions 93 References 95 5 Management of Dyslipidemias: Principles and
Guidelines 99 5.1 Overview 99 5.2 General Principles of the Management of
Dyslipidemias 99 5.3 Current Evidence?]Based Guidelines on the Management
of Dyslipidemias 102 5.4 Summary of Chapter Key Points 113 5.5
Self?]Assessment Questions 113 References 114 UNIT III HYPERTENSION AND
MULTITASKING CARDIOVASCULAR DRUGS 117 6 Overview of Hypertension and Drug
Therapy 119 6.1 Introduction 119 6.2 Definitions, Classifications, and
Epidemiology of Hypertension 119 6.3 Pathophysiology of Hypertension 121
6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview 123 6.5
Summary of Chapter Key Points 123 6.6 Self?]Assessment Questions 125
References 125 7 Diuretics 127 7.1 Overview 127 7.2 Volume Regulation and
Drug Targeting 127 7.3 Thiazide and Thiazide?]Type Diuretics 129 7.4 Loop
Diuretics 134 7.5 Potassium?]Sparing Diuretics 138 7.6 Other Diuretics 142
7.7 Summary of Chapter Key Points 143 7.8 Self?]Assessment Questions 143
References 144 8 Sympatholytics 147 8.1 Overview 147 8.2 Sympathetic
Nervous System and Drug Targeting 147 8.3 alpha?]Adrenergic Receptor
Antagonists 150 8.4 ß?]Adrenergic Receptor Antagonists 150 8.5 Centrally
Acting Sympatholytics 157 8.6 Summary of Chapter Key Points 158 8.7
Self?]Assessment Questions 159 References 159 9 Inhibitors of the
Renin-Angiotensin-Aldosterone System 161 9.1 Overview 161 9.2 The RAAS and
Drug Targeting 161 9.3 Direct Renin Inhibitors 162 9.4 ACE Inhibitors 166
9.5 ARBs 174 9.6 Comparative Pharmacology of Direct Renin Inhibitors, ACE
Inhibitors, and ARBs 179 9.7 Summary of Chapter Key Points 181 9.8
Self-Assessment Questions 181 References 182 10 Calcium Channel Blockers
185 10.1 Overview 185 10.2 Calcium Channels and Drug Targeting 185 10.3
L-TYPE CCBs 186 10.4 Summary of Chapter Key Points 192 10.5 Self-Assessment
Questions 192 References 193 11 Nitrates and Other Vasodilators 194 11.1
Overview 194 11.2 Drug Class and Drug Targeting 194 11.3 Organic Nitrates
and Sodium Nitroprusside (Nitric Oxide?]Releasing Vasodilators) 196 11.4 ET
Receptor Antagonists 201 11.5 Phosphodiesterase 5 Inhibitors 204 11.6 sGC
Stimulators 207 11.7 K+ATP Channel Openers 209 11.8 Other Vasodilators 210
11.9 Summary of Chapter Key Points 212 11.10 Self-Assessment Questions 212
References 213 12 Management of Hypertension: Principles and Guidelines 215
12.1 Overview 215 12.2 Introduction to Current Guidelines for the
Management of Systemic Hypertension 215 12.3 Key Recommendations of Major
Guidelines for the Management of Systemic Hypertension 217 12.4 Lifestyle
Modifications for the Management of Systemic Hypertension 221 12.5 Drug
Therapy of Systemic Hypertension 223 12.6 Drug Therapy of Prehypertension
234 12.7 Drug Therapy of Pulmonary Hypertension 235 12.8 Summary of Chapter
Key Points 237 12.9 Self-Assessment Questions 238 References 239 UNIT IV
ISCHEMIC HEART DISEASE: STABLE ISCHEMIC HEART DISEASE 243 13 Overview of
Ischemic Heart Disease, Stable Angina, and Drug Therapy 245 13.1
Introduction 245 13.2 Classification, Epidemiology, and Pathophysiology 245
13.3 Stable Angina and Drug Targeting 250 13.4 Summary of Chapter Key
Points 252 13.5 Self-Assessment Questions 252 References 253 14 Drugs for
Stable Angina 254 14.1 Overview 254 14.2 ß-Blockers for Treating Stable
Angina 254 14.3 CCBs for Treating Stable Angina 255 14.4 Organic Nitrate
for Treating Stable Angina 255 14.5 New Antianginal Drugs: Ranolazine 255
14.6 Other New and Emerging Drugs 258 14.7 Summary of Chapter Key Points
259 14.8 Self-Assessment Questions 259 References 260 15 Management of
Stable Angina/Stable Ischemic Heart Disease: Principles and Guidelines 262
15.1 Overview 262 15.2 Introduction to Current Guidelines on Management of
Stable Angina/SIHD 262 15.3 General Principles of Management of Stable
Angina/SIHD 265 15.4 Current Guideline Recommendations on Stable
Angina/SIHD Management 266 15.5 Management of Special Types of Stable
Angina 271 15.6 Summary of Chapter Key Points 273 15.7 Self-Assessment
Questions 273 References 273 UNIT V ISCHEMIC HEART DISEASE: ACUTE CORONARY
SYNDROMES 275 16 Overview of Acute Coronary Syndromes and Drug Therapy 277
16.1 Introduction 277 16.2 Definitions and General Considerations 277 16.3
Pathophysiology and Drug Targeting 278 16.4 Summary of Chapter Key Points
280 16.5 Self-Assessment Questions 281 References 281 17 Anticoagulants,
Platelet Inhibitors, and Thrombolytic Agents 283 17.1 Overview 283 17.2
Hemostasis 283 17.3 Anticoagulants 285 17.4 Platelet Inhibitors 295 17.5
Thrombolytic Agents 304 17.6 Summary of Chapter Key Points 307 17.7
Self-Assessment Questions 307 References 308 18 Management of Unstable
Angina and Non-ST-Elevation Myocardial Infarction: Principles and
Guidelines 310 18.1 Overview 310 18.2 Introduction to Evidence-Based
Guidelines 310 18.3 General Principles of Management of UA/NSTEMI 311 18.4
Guideline-Based Recommendations on the Management of UA/NSTEMI 311 18.5
Summary of Chapter Key Points 324 18.6 Self-Assessment Questions 325
References 325 19 Management of ST-Elevation Myocardial Infarction:
Principles and Guidelines 327 19.1 Overview 327 19.2 Definition and
Epidemiology 327 19.3 Introduction to Recent Guidelines on the Management
of STEMI 328 19.4 Principles and Guideline Recommendations for the
Management of STEMI 329 19.5 Summary of Chapter Key Points 339 19.6
Self-Assessment Questions 340 References 340 UNIT VI HEART FAILURE 343 20
Overview of Heart Failure and Drug Therapy 345 20.1 Introduction 345 20.2
Definition, Classification, and Epidemiology 345 20.3 Pathophysiology and
Drug Targeting 348 20.4 Summary of Chapter Key Points 349 20.5
Self-Assessment Questions 350 References 350 21 Drugs for Heart Failure 352
21.1 Overview 352 21.2 Diuretics for Heart Failure 352 21.3 ß-Blockers for
HF 352 21.4 Inhibitors of the RAAS for HF 353 21.5 Vasodilators for HF 354
21.6 Positive Inotropic Agents for HF 354 21.7 Emerging Drugs for HF 359
21.8 Summary of Chapter Key Points 360 21.9 Self-Assessment Questions 360
References 361 22 Management of Heart Failure: Principles and Guidelines
364 22.1 Overview 364 22.2 Management of Hf-REF 364 22.3 Management of
HF-PEF 367 22.4 Management of Acute Heart Failure Syndromes 368 22.5
Summary of Chapter Key Points 372 22.6 Self-Assessment Questions 373
References 374 UNIT Vii CARDIAC ARRHYTHMIAS 375 23 Overview of Cardiac
Arrhythmias and Drug Therapy 377 23.1 Introduction 377 23.2 Definition,
Classification, and Epidemiology 377 23.3 Pathophysiology and Drug
Targeting 380 23.4 Summary of Chapter Key Points 388 23.5 Self-Assessment
Questions 389 References 390 24 Drugs for Cardiac Arrhythmias 391 24.1
Overview 391 24.2 Classification of Antiarrhythmic Drugs 391 24.3 Class I
Antiarrhythmic Drugs 392 24.4 Class II Antiarrhythmic Drugs 398 24.5 Class
III Antiarrhythmic Drugs 399 24.6 Class IV Antiarrhythmic Drugs 404 24.7
Other Antiarrhythmic Drugs 406 24.8 Summary of Chapter Key Points 408 24.9
Self-Assessment Questions 409 References 410 25 Management of Cardiac
Arrhythmias: Principles and Guidelines 411 25.1 Overview 411 25.2 General
Principles of Management 411 25.3 Management of Supraventricular
Arrhythmias 411 25.4 Management of Ventricular Arrhythmias 414 25.5 Summary
of Chapter Key Points 421 25.6 Self-Assessment Questions 423 References 424
UNIT Viii ISCHEMIC STROKE 427 26 Overview of Ischemic Stroke and Drug
Therapy 429 26.1 Introduction 429 26.2 Definition and Classification of
Cerebrovascular Diseases 429 26.3 Definition and Classification of Stroke
429 26.4 Epidemiology of Stroke 430 26.5 Risk Factors of Stroke 432 26.6
Pathophysiology of Ischemic Stroke and Drug Targeting 432 26.7 Summary of
Chapter Key Points 434 26.8 Self?]Assessment Questions 434 References 435
27 Drugs for Ischemic Stroke 436 27.1 Overview 436 27.2 Drugs for Primary
Prevention of Ischemic Stroke 436 27.3 Drugs for Early Treatment of Acute
Ischemic Stroke 438 27.4 Drugs for Neuroprotection 439 27.5 Drugs for
Secondary Prevention of Ischemic Stroke 441 27.6 Stem Cell Therapy for
Neurorepair 442 27.7 Summary of Chapter Key Points 442 27.8 Self-Assessment
Questions 443 References 444 28 Management of Ischemic Stroke: Principles
and Guidelines 447 28.1 Overview 447 28.2 Introduction to Stroke Systems of
Care 447 28.3 Current AHA/ASA Guidelines on Early Management of Acute
Ischemic Stroke 449 28.4 Summary of Chapter Key Points 450 28.5
Self-Assessment Questions 455 References 456 INDEX 457